Impact of activated monocyte and endothelial dysfunction on coagulopathy in Egyptian adult beta thalassemic patients

Hanaa Abd El-samee,1 Noha Bassiouony,2 Nermeen Nabih1
1Department of Internal Medicine, Clinical Hematology Division; 2Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Abstract

The mechanism of the well observed hypercoagulability and high incidence of Thromboembolic Events (TE) in β-thalassemia patients has not been fully elucidated. This study aimed to evaluate the endothelial dysfunction and monocyte activation among adult Egyptian β-thalassemic patients and assess their role in the hypercoagulability and development of TE. A total of 40 adults patients with β-thalassemia and 20 healthy age and sex-matched controls were assessed for endothelial dysfunction using serum Von Willebrand Factor Antigen (VWF:Ag) and for monocyte activation using flow cytometric assessment of CD14 monocyte microparticles and CD11b activated monocytes. The VWF:Ag level was significantly higher among thalassemic patients (P<0.001) and was positively correlated to development of TE (P<0.05). There was no significance difference for CD14 between patients and controls (P>0.5) and CD11b was higher in controls (P=0.004) with no significant correlation between both and TE development (P=0.05). VWF:Ag is increased in thalassemic patients and could be used as a risk factor for thrombosis in these patients, while no identified role of activated monocytes in thrombotic tendency in such patients.

Introduction

Beta-thalassaemia is a monogenic inherited hemoglobin disorder leading to reduced or absent synthesis of the beta-globin subunit of adult haemoglobin.1 It is characterized by ineffective erythropoiesis, haemolytic anaemia, and subsequent clinical complications that require Life long disease management.2

The survival and quality of life of patients with beta-thalassaemia in developed countries have improved markedly in recent decades as a result of regular blood transfusions and compliance with tight iron chelation therapy. However, β-thalassemia patients, still suffer from a series of serious complications of their chronic disease, including hypercoagulability and thromboembolic events which lead to significant morbidity and mortality in β-thalassaemia.3,4

The molecular and cellular mechanisms contributing to hypercoagulable states in thalassaemia are diverse and have not been fully elucidated. It is considered multifactorial with numerous factors have been considered to be involved in, such as endothelial cell dysfunction, abnormal RBCs due to changes in membrane phospholipid asymmetry of RBCs and activation of other blood cells, including monocytes, granulocytes and chronic platelet activation.5

The endothelium is a key regulator of vascular homeostasis. Activated endothelial cells tend to prothrombotic properties through the imbalance in expression of anticoagulant and procoagulant factors, adhesion molecules and proinflammatory cytokines.5,7 It is hypothesized that monocytes are activated and plays a role in coagulopathy in β-thalassemia by activating endothelium.8

Multiple pathways for monocyte activation in β-thalassemia have been suggested such as the presence of increased number of RBC microparticles, RBC-derived hemoglobin and heme-derived oxidants and may be in vivo activated endothelium that primes the monocyte.9

Microparticles (MP) are intact vesicles derived from cell membranes which arise mainly through cell membrane activation processes and from apoptosis.10,11 Monocyte Microparticles (MMPs) have vital role in inflammation, blood coagulation, and endothelial cell functions. Identification of monocyte Microparticles (mMPs) is based on phosphatidylserine and CD14 expression on their surface.11 When activated monocytes conjugate with platelets, the latter activates expression of CD11b/CD18 (macrophage-1 antigen, Mac-1) on monocytes which amplifies its interactions with platelets via fibrinogen bivalent linking Mac-1 with platelet glycoprotein IIb/IIIa. Expression of Mac-1 mediate the adhesive properties of leukocytes and accelerate their shedding of thrombogenic microparticles.12

The objective of this study was to evaluate the endothelial dysfunction and monocyte activation among adult Egyptian β-thalassemic patients and assess their role in the hypercoaguable states and development of Thrombotic events in such patients by assessment of Von Willebrand Factor
Antigen (VWF:Ag) as endothelial activation marker and flow cytometric analysis of CD14 circulating monocytic Microparticles (mMps) and CD11b activated monocytes.

Materials and Methods

Subjects

The current case control study was conducted in the Adult Clinical hematology Division, Internal medicine Department, Ain Shams University Hospitals, Cairo, Egypt. 40 adult β-thalassemia patients were recruited from clinical hematology outpatient clinic during their routine follow up between October 2018 and March 2019. Twenty age and sex matched healthy volunteers were enrolled as a control group. All included patients were subjected to detailed medical history and thorough clinical examination with special emphasis on disease duration, history of splenectomy, viral hepatitis, transfusion history (age of starting transfusion, frequency of transfusion with calculation of transfusion index, detailed chelation therapy, compliance to treatment including chelation therapy and history of any recent or past arterial or venous Thromboembolic events. All patients were subjected to the routine diagnostic work-up for hemolytic anemia including (CBC, reticulocytic count, LDH, and hemoglobin electrophoresis), liver function tests and renal function tests. Flow cytometric assessment of CD14 and CD11b as markers of monocytic activation and plasma VWF:Ag assay. Patients who had any of the following conditions were excluded from the study: Thalassemic patients other than β-thalassemia, Thalassemic patients who are on long term anticoagulation or antiplatelets or have end stage kidney or liver disease, and Thalassemic patients who have other risk factors of thrombosis as pregnancy, diabetes and smoking. All participants were informed about the objectives and procedures of the study and written informed consents were obtained prior to enrollment and the procedures applied in this study were approved by the Ethical Committee of the Ain Shams University hospitals and are in accordance with the Helsinki Declaration of 1975.

Methods

A volume of 6mL of Peripheral venous blood was collected and divided. The first 2mL was collected on a tube Ethylene diamine tetra-acetate (EDTA) (2.2mg/mL), for for complete blood count (CBC), preparation of Leishman stained PB smears, reticulocyte count and Hb electrophoresis. Another 2mL of PB on sterile K2-EDTA was collected for CD 14 and CD11b analysis using Beckman Coulter flowcytometry (Beckman Coulter, Brea, CA) at flow cytometry laboratory in faculty of medicine Ain Shams University and 2mL of blood was collected with 3.8% sodium citrate as anticoagulant to measure VWF:Ag level. Quantitative VWF:Ag assay was performed on a Sysmex CA-1500 coagulation analyzer (Siemens Healthcare Diagnostics, Marburg, Germany) with a normal range between 50% and 150% at immunology laboratory in faculty of medicine Ain Shams University.

Statistical analysis

Data were analyzed using Statas® version 14.2 (StataCorp LLC, College Station, TX, USA). Normality of numerical data distribution was examined using the Shapiro-Wilk test. Non-Normally distributed numerical data were presented as median and interquartile and intergroup differences were compared using the Wilcoxon rank sum test (for two-group comparison) or the Jonckheere-Terpstra trend test (for comparison of multiple tanked grouped). Categorical data were presented as ratio or number and percentage and intergroup differences were compared using Fisher’s exact test (for nominal data) or the chi-squared test for trend (for ordinal data). Correlations among numerical variables were tested using the Spearman rank correlation. The probability of error (p) at 0.05 was considered significant, while at 0.01 and 0.001 are highly significant and >0.05 is insignificant.

Results

Fifty β-thalassemia patients, including 23 (57.5%) males and 17 (42.5%) females with a male to female ratio of 1.2:1 and an age range of 20-26 years, with a mean age of (23±4) years. Thirteen patients presented with thalassemia major (32.5%), twenty two with thalassemia intermediate patients (55.0%) and five patients with thalassemia minor (12.5%). Splenectomy was done to eleven (27.5%) of these patients, only fifteen (37.5%) of patients were compliant to Iron chelation therapy and seven patients (17.5%) gives history of thromboembolic events. While the healthy control group, they were 11 (56.7%) male and 9 (43.3%) female with a male to female ratio of 1.2:1. Their ages ranged from 21-28 years, with a mean of age 23.35±4.61 years. Demographic and clinico-laboratory data of patients’ group are shown in Table 1. On comparing the studied adult beta thalassemia patients and the healthy controls, they were age and sex matched while their laboratory results revealed that thalassemia patients have statistically significant high increase in the level of platelets and WBCs than control with p-value <0.001 and <0.001 respectively also Liver enzymes SGPT & SGOT were significantly higher in thalassemia patients as p-value =0.008 and 0.004 (Table 2).

Comparison of plasma VWF Ag, CD14 and CD11b among patients with β thalassemia and healthy control

Patients with β thalassemia had significantly higher VWF:Ag levels than that of controls (P<0.001), while CD11b level was significantly lower in patients than controls (P=0.004) however no statistically significant difference was found in CD14 level between patients and healthy controls (P=0.5) (Table 2, Figure 1).

While upon comparing VWFAg, CD14, CD11b levels between the different types of β thalassemia there was no statistically significant difference between the different types (P=0.45, 0.80, 0.56 respectively).

Relation between VWF:Ag, CD14 and CD11b and different laboratory characteristics of patients with thalassemia

No significant correlations were found between VWF:Ag and CD14 or CD11b while a significant positive correlation was found between CD14 level and CD11b level (rho=0.443, p=0.004) and a significant

Table 1. Demographic and clinical data of studied thalassemia patients.

| Variable                 | Value       |
|-------------------------|-------------|
| Age (years)             | 23±4        |
| Gender                  |             |
| M                       | 23 (57.5%)  |
| F                       | 17 (42.5%)  |
| Type of thalassemia     |             |
| Thalassemia minor       | 5 (12.5%)   |
| Thalassemia intermedia  | 22 (55.0%)  |
| Thalassemia major       | 13 (32.5%)  |
| Iron chelation therapy  | 15 (37.5%)  |
| Splenectomy             | 11 (27.5%)  |
| SGPT (IU/L)             | 52 (31-76)  |
| SGOT (IU/L)             | 51 (31-73)  |
| Urea (mg/dl)            | 25±4 4.2    |
| Creatinine (mg/dl)      | 0.7±0.2     |
| Hemoglobin (g/dl)       | 6.7±1.6     |
| WBCs (x1000/mm³)        | 9.1 (6.6-13.7) |
| Platelets (x1000/mm³)   | 449 (303-720) |
| VWF:Ag (IU/dl)          | 3.98 (1.63-6.00) |

Data are mean ± SD, number (%) or median (interquartile range).
negative correlation was observed between CD11b and both platelets count (rho=0.399, P =0.01) and White blood cell count (rho=0.368, P=0.02).

Relation between different clinicopathological characteristics of thalassemia patients and the development of thrombotic events

The current study results suggest that splenectomy could be considered a significant risk factor for thrombosis as 71.4% of patients who developed TE, had been splenectomized with p-value=0.01, there is a statistically significant relation between splenectomy and Thromboembolism (TE) with an odds ratio of 11.25 (95% CI=1.75 to 72.50, p-value=0.011). On the other hand compliance to iron chelator therapy had no statistically significant impact on the development of thrombotic event (P=0.6) (Table 3). The data of the present study confirmed that Platelet count is a significant risk factor for TE development as (p-value<0.001) (Table 4).

Receiver-Operating Characteristic (ROC) curve analysis was used to determine the cut off value of platelet count, vWF:Ag, CD14 or CD11b for development of thrombotic events. When assessing the best cut off value of platelet count in discriminating thalassemic patients who are at high risk for development of thrombotic events the area under the curve (AUC) was.924, suggesting that Patients with platelets count >770,000/mm³ are at high risk for TE development with a sensitivity of 85.7% and specificity of 90.9%.

Relation between vascular dysfunction marker, activated monocytes and monocyte microparticles and the development of thrombotic events of thalassemia patients

The present study revealed that VWF:Ag level which is a marker of vascular endothelial dysfunction, is a good marker for TE development in the studied thalassemia patients as it has a statistically significant positive correlation with development of TE (P<0.05) and the discriminative value of vWF level was good (AUC=0.871). Patients with vWFa level >7 IU/dL are considered at high risk for TE development with a sensitivity of 42.9% and specificity of 93.9%. On the other hand this study revealed that both CD11b level as a marker of activated monocytes and CD14 level (expressed on monocyte microparticles) are not considered as risk factor for development of TE in thalassemic patients as no significant correlation was found between both of them and development of TE (p-value>.05) (Table 4, Figure 1).

Table 2. Comparison between studied thalassemia patients and healthy control.

| Variable         | Control (n=20) | Thalassemia (n=40) | p-value |
|------------------|----------------|--------------------|--------|
| Age (years)      | 22 (20 – 26)   | 21 (20–26)         | .0800\*|
| Gender (M/F)     | 19/1          | 23/17              | 1.000\*|
| Platelets (x1000/ml³) | 266 (213 – 298) | 449 (303–720)     | <.001\*|
| WBCs (x1000/mm³) | 5.69 (5.35 – 7.80) | 9.10 (6.60–13.85) | .002\*|
| Hemoglobin (g/dL) | 13.1 (12.0 – 13.9) | 6.7 (5.5–7.9)     | <.001\*|
| Creatinine (mg/mL) | 0.7 (0.5 – 0.8) | 0.7 (0.6–0.8)      | .173\*|
| SGOT (IU/l)      | 30 (23 – 38)   | 31 (31–73)         | .004\*|
| SGPT (IU/l)      | 52 (31 – 76)   | 52 (31–76)         | .006\*|
| Urea (mg/dL)     | 25.5 (20.5 29.0) | 26.0 (22.0–29.0)  | .620\*|
| SGOT (IU/l)      | 32 (26 – 40)   | 31 (31–73)         | .004\*|
| Creatinine (mg/mL) | 0.7 (0.5 – 0.8) | 0.7 (0.6–0.8)      | .173\*|
| Hemoglobin (g/dL) | 13.1 (12.0 – 13.9) | 6.7 (5.5–7.9)     | <.001\*|
| WBCs (x1000/mm³) | 5.69 (5.35 – 7.80) | 9.10 (6.60–13.85) | .002\*|
| Platelets (x1000/ml³) | 266 (213 – 298) | 449 (303–720)     | <.001\*|
| vWFa (IU/dL)     | 0.89 (0.61 – 1.40) | 3.98 (1.65–6.00)  | <.001\*|
| CD14 (µg/mL)     | 5.43 (4.04 – 7.58) | 4.80 (2.82–6.77)  | .204\*|

value>.05 (Table 4, Figure 1).

Table 3. Correlation between demographic and clinical variables and the development of thrombotic events in thalassemia patients.

| Variable         | No history of TE (n=33) | History of TE (n=7) | p-value |
|------------------|-------------------------|---------------------|--------|
| Age (years)      | 22 (20 – 26)            | 20 (19 – 21)        | .217\*|
| Gender (M/F)     | 19/14                   | 4/3                 | 1.000\*|
| Type of thalasemia |                         |                     | .095\*|
| Thalassemia minor| 5 (15.2%)               | 0 (0.0%)            |       |
| Thalassemia intermedia | 19 (57.6%) | 3 (42.9%)           |       |
| Thalassemia major | 9 (27.3%)               | 4 (57.1%)           |       |
| Splenectomy      | 6 (18.2%)               | 5 (71.4%)           | .011\*|
| Iron chelation therapy | 13 (39.4%) | 2 (28.6%)           | .691\*|

Data are ratio, median (interquartile range) or number (%). \*Fisher’s exact test. \*Wilcoxon rank sum test. \*Chi-squared test for trend test.


Discussion

Currently hypercoagulable state is a well described complication in β-thalassemia and is associated with increased risk for thromboembolic complications in such patients however, the underlying mechanisms has not been fully elucidated.13-15

β-thalassemia is a common hematologic disorder in the Mediterranean basin, parts of North and West Africa, the Middle East, India, the Southern Far East, and Southeast Asia; these areas make up the so-called thalassemia belt.14 Particularly in Egypt, β-thalassemia has been the most common type of hereditary anemia, with a carrier rate of approximately 10%, and it has been estimated that per 1.5 million annual live births, approximately 1000 babies are born with β-thalassemia major however little is known about the clinical associations of markers of hypercoagulability in the Egyptian thalassemia patients.15

In the present study, 40 thalassemic patients were evaluated for the presence of vascular endothelial activation using (VWF:Ag) level and for monocyte activation with microparticle formation by detection of CD11b, CD14 expression by flow cytometry analysis and to clarify their role in the hypercoagulability and development of thrombotic event in adult β-thalassemia patients.

The current study revealed significantly higher serum level of VWF:Ag in all thalassemics compared with the control group (P<0.001) confirming endothelial activation. This goes in agreement with both Adely et al., who have reported higher plasma VWF:Ag levels in patients with β-thalassemia, particularly those with evident heart disease,16 and Al-Harbi et al., who showed that VWF:Ag level is increased in most of thalassemic even if they were not splenectomized.17

However in the present study, there is no statistically significant difference was found in CD14 level between patients and healthy controls (P>0.5). Moreover CD11b level, which is a marker of monocyte activation, was significantly lower in patients than controls (P=0.004), these results were in agreement with both. Kheansaard et al., who have studied the origin and the effect of circulating microparticles in thalassemic and reported that the increased microparticles in thalassemia are not monocyntic derived and confirmed that other types of MPs play an important role on thrombosis and vascular dysfunction in β-thalassaemia,18 and Elsayeh et al., who reported an increase in the total MPs in thalassemic patients who had previous history of thrombosis or pulmonary hypertension, however monocyntic microparticles did not increase.19 This finding was explained by Slater et al., who reported that iron overload in thalassemic patients can modulate monocyntic functions and activation through inhibition of TLR4 (toll-like receptor 4) which is responsible for monocytes activation by TLR4 -endothelial signaling.20-21 The results of another studies were in contrast to this finding, as a recent study by Ghozali et al., who reported increased CD14+ monocytes in β-thalassaemia and highlighted its major role in the state of chronic inflammation in such patients.22 This discrepancy in the results of different studies dealing with β-thalassemia patients, may be because of the heterogeneity of the studied β-thalassemia patients in their genotype, age, frequency of transfusions, and iron overload.

In the present study, the history of thrombotic event was found in 17.5% of the studied adult patients with β-thalassemia, which is in line with many previous studies confirming the presence of hypercoagulable state of β-thalassemia.23-24

The current study suggest that both Splenectomy and platelet count could be considered as risk factors for thrombosis p-value=0.01 and <0.001 respectively and 71.4% of patients who developed TE had been splenectomized. Karimi et al., were in agreement with the current study, they found that older age and splenectomized multi transfused β-thalassemic patients even with normal platelet count have a higher incidence of Silent Cerebral Ischemia and the effect of splenectomy is more significant in statistical analysis.25 Merchant et al., explained that splenectomy increases the hypercoagulability, by permitting the circulation of greater numbers of altered membranes cells, and by increasing the number of Platelet.26 The results of this study suggest that thalassemic patients with platelets count >770,000/mm³ are at higher risk for TE development than other patients with less platelets count AUC=0.924 with a sensitivity of 85.7% and specificity of 90.9%. Further more the present data revealed that VWF:Ag level, which is a marker of vascular endothelial dysfunction, is a good marker for TE development (P<0.05) and suggested that patients with VWFa level >7IU/U/L are considered at higher risk for TE development than other thalassemia patients with a sensitivity of 42.9% and specificity of 93.9%. This findings were in agreement with many previous studies which confirm that the contributing role of vascular endothelial dysfunction in the hypercoaguable state and thrombotic complication, the most recent one by Poredos et al., who reported that endothelial dysfunction was a particular characteristic of patients with unprovoked VTE and that impairment of endothelial function in patients with spontaneous VTE was significantly associated with higher levels of markers of endothelial activation in the plasma (eg, vWF and soluble P-

Table 4. Relation between laboratory variables, vWFa, CD14 and CD11b and the development of TE in thalassemic patients.

| Variable               | No history of TE (n=33) | History of TE (n=7) |
|------------------------|-------------------------|---------------------|
|                        | Median                  | Interquartile range | Median                  | Interquartile range | p-value[^\d] |
| SGPT (IU/L)            | 40                      | 31–70               | 51–90                   | 0.226                |
| SGOT (IU/L)            | 50                      | 31–65               | 48–110                  | 0.200                |
| Urea (mg/dL)           | 25.0                    | 21.0–29.0           | 25.0                    | 25.0–27.0            | 0.900        |
| Creatinine (mg/mL)     | 0.7                     | 0.6–0.80            | 0.6–0.8                 | 0.704                |
| Hemoglobin (g/dL)      | 6.7                     | 5.8–0.85            | 5.2–7.0                 | 0.219                |
| WBCs (x1000/mm³)       | 8.70                    | 6.4–12.00           | 15.0                    | 8.00–38.00           | 0.139        |
| Platelets (x1000/mm³)  | 400                     | 300–520             | 949                     | 800–1000             | <0.001       |
| vWFa (IU/U/L)          | 3.50                    | 1.80–5.50           | 5.00                    | 1.10–8.00            | <0.05        |
| CD14 (μg/ml)           | 5.15                    | 3.10–7.86           | 2.80                    | 2.33–4.91            | 0.067        |
| CD11b (μg/ml)          | 76.20                   | 64.80–83.50         | 54.90                   | 46.50–70.90          | 0.075        |

[^\d]: Data are median and interquartile range (interquartile range). "Wilcoxon rank sum test."
selectin). On the other hand the present study revealed that both CD11b level as a marker of activated monocytes and CD14 level (expressed on monocyte microparticles) are not considered as risk factor for development of TE in thalassemia patients as no significant correlation was found between both of them and development of TE (p-value=0.05) which may be attributed to iron overload state.

Conclusions

In conclusion, our results indicated that VWF:Ag is increased in Egyptian β-thalassemic patients and could be used as a surrogate marker for thrombotic tendency in these patients. It also seems reasonable to add assessment of VWF:Ag to the follow up laboratory investigations for thalassemic patients while no identified role of activated monocytes in hypercoagulability and thrombotic tendency in thalassemic patients. Establishment of thrombosis risk assessment model specific for thalassemics, including platelets count, splenectomy, VWF:Ag and other biological parameters to identify high risk thalassemic patients for thrombosis, is highly warranted for establishment of specific proper prophylactic antithrombotic plane for such patients.

References

1. Cappellini MD, Cohen A, Porter J, Taher A, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia, Cyprus: Thalassaemia International Federation; 2014.
2. Makis A, Efthieria H, Papaioioutiou I, Voskaridou E. Clinical trials update in new treatments of β-thalassemia. Am J Hematol 2016;91:1135-45.
3. Fibach E, Rachmilewitz EA. Pathophysiology and treatment of patients with beta-thalassemia – an update [version 1; referees: 2 approved]. F1000 Res 2017;6:2156. doi:10.12688/f1000research.12688.1.
4. Domenica M, Porter JB, Viprakasit V, Taher AT. A paradigm shift on beta-thalassemia treatment: How will we manage this old disease with new therapies? Blood Rev 2018;32:300–11.
5. Sirachainan N. Thalassemia and the hypercoagulable state. Thromb Res 2013;123:37-41.
6. Stoyanova E, Trudel M, Felfly H, et al. Vascular endothelial dysfunction in β-thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NO. PLoS One 2012;7.
7. Abd A, Abd E, Youssef SR, et al. Association of Activated Circulating Endothelial Cells with Vascular Complications in Egyptian Beta-Thalassemic Patients. J Blood Disord Transfus 2015;6:273.
8. Kyriakou DS, Alexandrakis MG, Kyriakou ES, et al. Activated peripheral blood and endothelial cells in thalassemia patients. Ann Hematol 2001;80:577–83.
9. Belcher JD, Marker PH, Weber JP, et al. Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vascular occlusion. Blood 2000;96:2451–9.
10. Levin C, Koren A, Reibbo-sabbah A, et al. Extracellular Vesicle Characteristics in β-thalassemia as Potential Biomarkers for Spleen Functional Status and Ineffective Erythropoiesis. Front Physiol 2018;9.
11. Abdul Halim AT, Mohd Ariffin NF, Azlan M. Review: the multiple roles of monocyte microparticles. Inflammation 2016;39:1277-84.
12. Simon DI, Ezratty AM, Francis SA, et al. Fibrin (ogen) is internalized and degraded by activated human monocytoid cells via Mac-1 (CD11b/CD18): a non plasmin fibrinolytic pathway. Blood 2013;82:2414–22.
13. Alhosiny M, Abdel-hady HE, Mohammed M, et al. Study of platelet activation, hypercoagulable state, and the association with pulmonary hypertension in children with b-thalassemia. Hematol Oncol Stem Cell Ther 2017;11:65-74.
14. Weatherall DJ. Keynote address: The challenge of thalassaemia for the developing countries. Ann NY Acad Sci 2005;1054:11-7.
15. Elmezayen AD, Kotb SM, Sadek NA, Abdalla EM. β-globin mutations in Egyptian patients with β-Thalassemia. Lab Med 2015;46:8–13.
16. Abdel A, Adly M, El-sherif NH, et al. Vascular dysfunction in patients with young b-thalassemia: relation to cardiovascular complications and subclinical atherosclerosis. Clin Appl Thromb Hemos 2015;21:733-44.
17. Al-Harbi KM, Shalaby SA, Baghdadi HH. Monocytes Activation and Some Haemostatic Parameters in Cases of α-Thalassemia. J Basic Appl Sci Res 2011;1:727-33.
18. Kheemsaaard W, Phongpao K, Paiboonsukw K, et al. Microparticles from β-thalassaemia / HbE patients induce endothelial cell dysfunction. Sci Rep 2018;8:1-11.
19. Elsayh KI, Zahran AM, El-abaseri TB, et al. Hypoxia Biomarkers, Oxidative Stress, and Circulating Microparticles in Pediatric Patients With Thalassemia in Upper Egypt. Clin Appl Thromb Hemos 2014;20:536-45.
20. Slater NR, Harmatz PR, Hospital C, et al. Iron overload and hemolysis modulate monocytes and inflammation in β-thalassemia. Free Radic Biol Med 2014;76:138.
21. Ward JR, Francis SE, Marsden L, et al. A central role for monocytes in Toll-like receptor-mediated activation of the vasculature. Immunology 2009;4:58–68.
22. Ghozali M, Anggia MF, Tjahjadi AI, Reniarti L. Positive Correlation between Ferritin and Activated Monocyte in Iron Overloaded Major β-thalassaemia Patients. Hiroshima J Med Sci 2018;67:78–83.
23. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev 2008;22:283–92.
24. Cappellini MD, Poggiali E, Taher AT, Musallam KM. Hypercoagulability in β-thalassemia: A status quo. Expert Rev Hematol 2012;5:505–12.
25. Karimi M, Toosi F, Haghpanah S, et al. The frequency of silent cerebral ischemia in patients with transfusion-dependent β-thalassemia major. Ann Hematol 2016;95:135-9.
26. Merchant RH, Shah AR, Ahmad J, et al. Post Splenectomy Outcome in β-Thalassemia. Indian J Pediatr 2015;82:1097–100.
27. Poredos P, Jezovnik MK. Endothelial dysfunction and venous thrombosis. Angiology 2018;69:564–7.

Hematology Reports 2020; 12:8365